In the News

COLUMBIA, S.C. (May 9, 2023) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose vial product, Albuterol Sulfate Inhalation Solution 0.5% (5 mg/mL). It is a ready-to-use drug shortage solution for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 27-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

COLUMBIA, S.C. (April 25, 2023) – The Ritedose Corporation (Ritedose), an industry leader in pharmaceutical development, aseptic cGMP manufacturing and 503B outsourcing solutions, has begun production of a particular form of Albuterol Sulfate that the FDA has listed in short supply in the United States. It will be available in May.

COLUMBIA, S.C. (April 13, 2023) – Ritedose, a pharmaceutical manufacturer located in South Carolina, just launched a new single unit dose oral inhalation product, Arformoterol Tartrate (15 mcg/2 ml), making the company the largest generic drug maker of its kind. Ritedose Pharmaceuticals is a division of The Ritedose Corporation, a 25-year-leader in cGMP drug manufacturing for major pharmaceutical companies, research development programs, hospitals, wholesalers and pharmacies.

COLUMBIA, S.C. (January 30, 2023) – Ritedose, a 503B outsourcing facility located in South Carolina, has been awarded a group purchasing agreement with Premier Inc., a leading healthcare improvement company operating one of the nation’s largest group purchasing organizations (GPOs). Effective January 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Ritedose’s full range of compounded medications.

COLUMBIA, S.C. (November 17, 2022) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched two new unit dose syringe products, Bupivacaine Hydrocholoride 0.25% (2.5 mg/mL) and Bupivacaine Hydrocholoride 0.5% (5 mg/mL). They are ready-to-use drug shortage solutions for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 27-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

COLUMBIA, S.C. (October 17, 2022) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched a new unit dose syringe product, Lidocaine Hydrochloride 1% 100 mg/10 mL. It is a ready-to-use drug shortage solution for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 27-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.

COLUMBIA, S.C. (February 14, 2022) – Ritedose, a 25-year industry veteran in pharmaceutical development and cGMP manufacturing, just launched two new 503B critical care, unit dose syringe products – Rocuronium Bromide Injection 50 mg/5mL and Rocuronium Bromide Injection 100 mg/10mL. Ritedose 503B Outsourcing Facility is a division of Ritedose.

COLUMBIA, S.C. (January 18) — The Ritedose Corporation has announced the development of and plans to commercialize the first new way to dispense single-dose liquid medications in two decades. After five years of R&D, the Columbia-based developer of blow-fill-seal unit dose technology is launching SuredoseRx™, an easier and more convenient way for healthcare workers to administer, and patients to take, single doses of liquid medications.